{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreidnf34yl4lxn3ovd73w6olm4jsbbvgxhwtjnzmry6dqd7wxrfarlu",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mnb2o2de2oa2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreigdrcumbfvhlfpoq7wnondqjgxyf5lx7jgg7v5e4aqr4rij7hm2qq"
    },
    "mimeType": "image/jpeg",
    "size": 196133
  },
  "path": "/2026/06/01/abivax-ulcerative-colitis-obefazimod/?utm_campaign=rss",
  "publishedAt": "2026-06-01T21:31:11.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Biotech",
    "biotechnology",
    "chronic diseases",
    "drug development",
    "Pharmaceuticals",
    "STAT+"
  ],
  "textContent": "Abivax said its experimental treatment for ulcerative colitis showed significant efficacy in a closely watched trial, but shares of the company tanked on safety concerns.",
  "title": "STAT+: Abivax ulcerative colitis drug shows strong efficacy, but cases of cancer raise concerns",
  "updatedAt": "2026-06-01T21:38:41.000Z"
}